ISPOR Glasgow 2017 Scientific Contributions

Listen in as our researchers share insights about research presented at ISPOR Glasgow.
Scroll down to see all of our presented research.

Saturday, 4 November | ISPOR Pre-conference Short Courses
8:00–12:00   Conjoint analysis – theory & methodsHauber AB, Bridges JFP
13:00–17:00   Collecting health-state utility estimates for economic models in clinical studies. Wolowacz S, Briggs A, Lloyd A, Doward L
Sunday, 5 November | ISPOR Pre-conference Short Courses
8:00–12:00   Budget impact analysis I: a 6-step approachEarnshaw SR, Mullins CD, Brodtkorb TH
13:00–17:00   Budget impact analysis II: applications & design issuesEarnshaw SR, Brogan AJ, Brodtkorb TH
Monday, 6 November | ISPOR Scientific Session Contributions - Posters
8:45–13:45 Session I Preferences for survival in non-small cell lung cancer: swinging for home runs or base hits? (PCN213) Hauber AB, Penrod JR, Gebben D, Musallam L
8:45–13:45 Session I Patient preferences in colorectal adenoma surveillance. (PCN218) McFerran E, Boeri M, McVicar D, Kee F
15:45–19:30 Session II Cost-effectiveness analysis of secukinumab in ankylosing spondylitis: a Canadian perspective. (PMS43) Chiva-Razavi S, Jain M, Graham CN, Miles L, Nikoglou E, Gunda P
15:45–19:30 Session II Cost-effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. (PMS44) Emery P, van Keep M, Beard SM, Graham CN, Miles L, Jugl SM, Gunda P, Halliday A, Marzo-Ortega H
15:45–19:30 Session II Cost-effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. (PMS54) Kirkham B, Buchanan V, Sullivan W, Graham CN, Miles L, Jugl SM, Gunda P, Halliday A
15:45–19:30 Session II Direct medical costs of hypoglycemia hospitalizations in the United States. (PHS30) Goyal RK, Sura SD, Mehta HB
15:45–19:30 Session II How does the Scottish medicines consortium assess the value of orphan and ultra-orphan drugs? (PSY137) Rothwell B
Tuesday, 7 November | ISPOR Scientific Session Contributions - Posters
8:45–13:30 Session III Development of a new patient-reported outcome measure for non-alcoholic steatohepatitis: NASH-check. (PGI39) Twiss J, Balp M, Doward L, Slota C, Cryer D, Langford A, Collen R, Agashivala N, Brass C, Sanyal A, Anstee QM
8:45–13:30 Session III Do budget impact analyses for screening of cancers follow international guidelines? A systematic review. (PMD27) Jahn B, Todorovic J, Bundo M, Sroczynski G, Conrads-Frank A, Rochau U, Chhatwal J, Mauskopf J, Siebert U
15:30–19:15 Session IV Adequately reflecting the clinical benefits in rare disease economic modeling using SMA Type I as a case study. (PND25) Zuluaga S, Knight C, Thompson R, Teynor M
15:30–19:15 Session IV Conceptual model and instrument review in multiple sclerosis. (PND53) Martin SA, Olayinka-Amao OC, Henke C, Kamudoni P, Gnanasakthy A
15:30–19:15 Session IV Association of multiple chronic conditions with health-related quality of life and physical functioning. (PHP208) Sura SD, Goyal RK, Adhikari D, Mehta HB
Wednesday, 8 November | ISPOR Scientific Session Contributions - Posters
8:45–14:00 Session V Secukinumab significantly reduces work impairment and indirect costs compared to ustekinumab and etanercept in the United Kingdom. (PSS22) Warren R, Halliday A, Graham CN, Gilloteau I, Miles L, Sherif B, McBride D  Research Presentation Award Finalist
8:45–14:00 Session V Recent trends in congenital cytomegalovirus-related hospitalization in the United States. (PIN35) Candrilli S, Trantham L Research Presentation Award Finalist
8:45–14:00 Session V Hepatitis A and hepatitis B recombinant vaccine adherence in the United States. (PIN72) Trantham L, Kurosky S, Zhang D, Johnson KD
8:45–14:00 Session V Inter-state variability of adult vaccination coverage in the United States: can we explain it? (PIN114) Kurosky S, Trantham L, La L, Aris E, Hogea C
8:45–14:00 Session V IQWIG´s general methods 5.0 - what´s new? (PRM27) Krieger T
8:45–14:00 Session V Adjusting for selection bias in evaluating two-dose human papillomavirus vaccine coverage among adolescents in the United States. (PRM76) Kurosky S, Trantham L
8:45–14:00 Session V Ethical considerations: conducting retrospective non-interventional medical record review studies in Europe. (PRM82) Levine CA, Ansquer V
8:45–14:00 Session V Assessing the robustness of network meta-analysis of atypical antipsychotics in the presence of heterogeneity. (PRM203) Ainsworth CM, Vickers AD, Le Moine J
8:45–14:00 Session V Assessing the robustness of direct meta-analysis in the presence of heterogeneity. (PRM223) Ainsworth CM